Icothera

Icodextrin, the active ingredient in Icothera, is an osmotic agent presented as a sterile solution for intraperitoneal infusion. It creates an osmotic gradient that enhances ultrafiltration during peritoneal dialysis in patients with end‑stage renal disease.

GNH USA supplies Icothera as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and dialysis clinics worldwide, providing reliable access to this peritoneal dialysis solution for renal care programs. Manufactured under EU regulations, the product meets stringent quality standards for safety and efficacy.

Icothera, an osmotic agent used in peritoneal dialysis, is indicated for renal replacement therapy in end‑stage renal disease.

End‑stage renal disease (ESRD): supports fluid removal and solute clearance during peritoneal dialysis. Continuous ambulatory peritoneal dialysis (CAPD): provides sustained ultrafiltration over multiple exchanges. Automated peritoneal dialysis (APD): enables efficient ultrafiltration during nighttime cycles.

Common Side Effects: - Abdominal discomfort or pain during exchanges. - Nausea or mild gastrointestinal upset. - Headache or dizziness. - Cough or mild respiratory irritation. - Skin rash or localized erythema. - Transient increase in peritoneal transport rates.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis. - Peritonitis with abdominal pain, fever, and cloudy effluent. - Metabolic acidosis or significant electrolyte imbalance. - Hyperosmolar state leading to hypotension. - Severe hyperglycemia in diabetic patients. - Rare cases of pulmonary edema due to fluid overload.

Precautions should be observed when using Icothera for peritoneal dialysis.

Monitor fluid balance: assess patient weight and ultrafiltration volume regularly. Assess peritoneal membrane function: evaluate transport characteristics before and during therapy. Avoid concurrent high‑glucose dialysis solutions: may diminish icodextrin efficacy. Caution in hepatic impairment: altered metabolism may increase systemic exposure. Hypersensitivity: discontinue if signs of allergic reaction appear. Store at controlled room temperature: keep in original container, protect from light and freeze.

Potential drug interactions must be considered when prescribing Icothera.

Major Interactions (Avoid): - Known hypersensitivity to icodextrin or any excipient: contraindicated. - Co‑administration with maltose‑containing dialysis solutions: may cause false hyperglycemia readings. - Concurrent use of systemic hyperosmolar agents (e.g., mannitol): risk of excessive fluid shifts.

Moderate Interactions (Monitor Closely): - Alpha‑glucosidase inhibitors (e.g., acarbose): may increase icodextrin metabolites. - High‑glucose peritoneal solutions: can reduce icodextrin ultrafiltration efficiency. - Certain antibiotics administered intraperitoneally: monitor for peritoneal irritation.